Procalcitonin or C-Reactive Protein: The better Identifier of Treatment Response in Urinary Tract Infection among Adults

Umer Naseer; Abdul Rehman Arshad; Bassam Khalid; Taimoor Saleem; Fatima Naseer; Mahnoor Qamar

doi:10.51253/pafmj.v76i1.9827

Authors

Umer Naseer Department of General Medicine, Combined Military Hospital Peshawar/National University of Medical Sciences (NUMS) Pakistan
Abdul Rehman Arshad Department of General Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Bassam Khalid Department of General Medicine, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Taimoor Saleem Department of General Medicine, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Fatima Naseer Department of General Medicine, Central Park Medical College, Lahore Pakistan
Mahnoor Qamar Department of General Medicine, Rashid Latif Khan University, Lahore Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i1.9827

Keywords:

C Reactive Protein, C Reactive Protein, Procalcitonin, urinary tract infection, UTI

Abstract

Objective: To ascertain the better marker between Procalcitonin and C reactive protein (CRP) in predicting response of treatment in patients suffering from urinary tract infections.

Study Design: Comparative cross sectional study.

Place and Duration of Study: Pak Emirates Military hospital, Rawalpindi Pakistan, from July 2020 to July 2021.

Methodology: It included individuals with clinical and laboratory evidence of isolated urinary tract infections. After consent, patients’ samples for baseline investigations (including urine cultures, Procalcitonin and CRP) were taken before the start of tablet Nitrofurantoin (100 mg twice daily 500mg daily for 7 days) and on third day of treatment. Outcomes of treatment were also recorded. Treatment of non-responders was later modified as per culture reports.

Results: A total of 200 individuals were included in the study. It comprised of 185(92.5%) females and 15 (7.5%) males. Their mean age was 40.4±9.64 years. Out of these subjects, 179 (89.5%) individuals recovered with the first line empirical antibiotic while 21 (10.5%) did not respond to it. 152 (76.0%) cultures showed organism growth with most common ones being Escherichia Coli (42.5%), Klebsiella spp(12.5%), Enterococcus(12.5%) and Pseudomonas spp (4%).Mean serum Procalcitonin levels on day zero and day 3 were 0.53±0.2 and 0.44±0.17 respectively. Similarly, mean serum CRP levels on day zero and day 3 were 74.4±24.9 and 61.97±21.6 respectively. Percentage fall of Procalcitonin and CRP on third day of antibiotic therapy was 16.01±8.4 and 15.96±8.58 respectively (p value 0.382).

Conclusion: There was no significant difference between Procalcitonin and CRP in predicting the response to ...

Downloads

Download data is not yet available.

References

1. Byron JK. Urinary Tract Infection. Vet Clin North Am Small Anim Pract 2019; 49(2): 211-221.

https://doi.org/10.1016/j.cvsm.2018.11.005

2. Neugent ML, Hulyalkar NV, Nguyen VH, Zimmern PE, De Nisco NJ. Advances in understanding the human urinary microbiome and its potential role in urinary tract infection. mBio 2020; 11(2): e00218-20. https://doi.org/10.1128/mbio.00218-20

3. Thomas-White KJ, Gao X, Lin H, Fok CS, Ghanayem K, Mueller ER, et al. Urinary microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. Int Urogynecol J 2018; 29(12): 1797-1805.

https://doi.org/10.1007/s00192-018-3767-3

4. Steinbach G, Bölke E, Grünert A, Orth K, Störck M. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr 2004; 116(24): 849-853.

5. Choi JJ, McCarthy MW, Meltzer KK, Cornelius-Schecter A, Jabri A et al. The Diagnostic Accuracy Of Procalcitonin for Urinary Tract Infection in Hospitalized Older Adults: a Prospective Study. J Gen Intern Med 2022: 1-7.

6. Mattoo TK, Shaikh N, Nelson CP. Contemporary management of urinary tract infection in children. J Pediatr 2021; 147(2): e2020012138. https://doi.org/10.1542/peds.2020-012138

7. Abou-Heidar NF, Degheili JA, Yacoubian AA, Khauli RB. Management of urinary tract infection in women: A practical approach for everyday practice. Urol Ann 2019; 11(4): 339.

8. Gajdács M, Ábrók M, Lázár A, Burián K. Increasing relevance of Gram-positive cocci in urinary tract infections: a 10-year analysis of their prevalence and resistance trends. Sci Rep 2020; 10(1): 1-1.

9. Peñalver-Penedo R, Rupérez -Lucas M, Álvarez-Sala Walther LA, Torregrosa-Benavent A, Casas-Losada ML et al. MR-Proadrenomedullin as biomarker of renal damage in urinary tract infection in children. BMC Pediatr 2021; 21(1): 1-8.

10. Hamade B, Huang DT. Procalcitonin: where are we now?. Crit Care Clin 2020; 36(1): 23-40.

https://doi.org/10.1016/j.ccc.2019.08.003

11. Zubair KU, Shah AH, Fawwad A, Sabir R, Butt A. Frequency of urinary tract infection and antibiotic sensitivity of uropathogens in patients with diabetes. Pak J Med Sci 2019; 35(6): 1664.

12. Baboudjian M, Gondran-Tellier B, Di Bisceglie M, Abdallah R, Michel F. The prognostic value of serum Procalcitonin in acute obstructive pyelonephritis. World J Urol 2021; 39(5): 1583-1589.

13. Tamadonfar KO, Omattage NS, Spaulding CN, Hultgren SJ. Reaching the End of the Line: Urinary Tract Infections. Microbiol Spectr 2019; 7(3): 10.

https://doi.org/10.1128/microbiolspec.BAI-0014-2019

14. Stalenhoef JE, van Nieuwkoop C, Wilson DC, van-der Starre WE, van-der Reijden TJ. Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection. BMC Infect Dis 2019; 19(1): 1-10.

https://doi.org/10.1186/s12879-019-3789-6

15. Kuil SD, Hidad S, Fischer JC, Harting J, Hertogh CM. Sensitivity of point-of-care testing C reactive protein and Procalcitonin to diagnose urinary tract infections in Dutch nursing homes: PROGRESS study protocol. BMJ Open 2019; 9(8): e031269.

https://doi.org/10.1136/bmjopen-2019-031269

16. Rasoulinasab M, Shahcheraghi F, Feizabadi MM, Nikmanesh B, Hajihasani A, Aslani MM. Distribution of ciprofloxacin-resistance genes among ST131 and non-ST131 clones of Escherichia coli isolates with ESBL phenotypes isolated from women with urinary tract infection. Iran J Microbiol 2021; 13(3): 294.

https://doi.org/10.18502/ijm.v13i3.6389

17. Gajdács M, Urbán E. Comparative epidemiology and resistance trends of proteae in urinary tract infections of inpatients and outpatients: a 10-year retrospective study. Antibiotics 2019; 8(3): 91.

18. AL-Khikani FH, Ayit AS. Correlation study between urinary tract bacterial infection and some acute inflammatory responses. Biomed Biotechnol Res J 2019; 3(4): 236.

https://doi.org/10.4103/bbrj.bbrj_122_19